Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2025eJHaemOpen Access

Dynamic Profiling of Cell Free Tumour DNA in Aggressive B‐Cell Lymphoma From Diagnosis to Transformation at Relapse

View Full Paper
Ask AI
Bookmark
Share

Authors

MWMark WalthamJWJonathan WongGPGalina Polekhina

Discussion

Loading...

Member takes

Overview

Prospective analysis illustrates ctDNA's role in profiling aggressive-B-cell lymphoma and early response predictions.

Key Points

  • Somatic mutations were found in 100% of patients at diagnosis, indicating tumor genomic diversity and burden.
  • Early molecular response predicted a complete metabolic response with a statistically significant p-value of 0.0014, showcasing predictive power.
  • Assessment using next generation sequencing (NGS) of ctDNA helped profile 17 patients during aggressive B-cell lymphoma treatment.
  • New findings suggest ctDNA analysis alone may not be sufficient for diagnosing late relapses due to shared mutations linked to varying histopathology.

Cite This Study

Waltham et al. (2025) studied this question.

synapsesocial.com/papers/68af494dad7bf08b1ead4c1ehttps://doi.org/10.1002/jha2.70126
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Liquid biopsy for molecular characterization of diffuse large B‐cell lymphoma and early assessment of minimal residual disease2024 · 27 citations
  2. 2Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas2025 · 1 citations
  3. 3Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring2026
  4. 4ctDNA for MRD Assessment is Prognostic and Predictive in Newly Diagnosed and Relapsed/Refractory Lymphoma2026
  5. 5Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy2024 · 20 citations